Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on February 8, 2017, detailing executive compensation arrangements for the 2016 fiscal year and 2017 fiscal year. The Compensation Committee of the Board of Directors approved 2016 bonuses and set 2017 base salaries for its key executive officers, including CEO John F. Milligan. Additionally, significant equity awards, consisting of stock options and performance shares, were granted to these officers. The compensation adjustments reflect the company's performance and the compensation committee's assessment of individual contributions. The equity awards, valued at the grant date fair value, are designed to align executive interests with shareholder value creation through performance-based metrics such as total shareholder return and revenue targets over multiple years. Investors should note these awards are subject to the terms of the company's 2004 Equity Incentive Plan.
Key Highlights
- 1Gilead's Compensation Committee set 2017 base salaries and determined 2016 bonus awards for its executive officers.
- 2CEO John F. Milligan received a 2016 bonus of $2,610,000 and a 2017 base salary of $1,545,000.
- 3Significant equity awards, including stock options and performance shares, were granted to key executives effective February 2, 2017.
- 4CEO John F. Milligan was granted equity awards with a total grant-date fair value of $11,500,000 ($5,750,000 in stock options and $5,750,000 in performance shares).
- 5Performance share awards are structured with a total shareholder return (TSR) tranche and a revenue tranche, divided into three annual subtranches.
- 6The equity awards are granted under Gilead's 2004 Equity Incentive Plan, with options having a ten-year maximum term.
- 7The independent members of the Board ratified the compensation decisions for the executive officers, including CEO John F. Milligan.